Literature DB >> 23426475

Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue.

David C Fajgenbaum, David Fajgenbaum1, Misha Rosenbach, Frits van Rhee, Adnan Nasir, Jason Reutter.   

Abstract

BACKGROUND: Eruptive cherry hemangiomatosis, which involves the sudden onset of multiple small vascular proliferations, has been rarely reported as a heralding sign of multicentric Castleman disease (MCD) and other lymphoproliferative diseases. We report a case wherein the rapid appearance of cherry hemangiomata is the presenting sign of MCD. OBSERVATIONS: A 25-year-old man with a 10-year history of benign vascular growths developed 23 cutaneous vascular proliferations and systemic symptoms 5 days prior to presentation. Biopsy of the cutaneous lesions revealed a polypoidal proliferation of vessels consistent with cherry hemangiomata. Laboratory studies disclosed systemic abnormalities, and the findings of a subsequent lymph node biopsy confirmed MCD. Combination chemotherapy was initiated, and the cutaneous proliferations improved in association with the systemic disease.
CONCLUSIONS: There is a scarcity of literature describing the association between eruptive cherry hemangiomatosis and MCD. The likely underlying mechanism is hypersecretion of vascular endothelial growth factor secondary to an elevated interleukin 6 level. Failure to recognize this association may have led to diagnostic delays. The authors suggest careful evaluation and follow-up of all patients presenting with the sudden onset of cherry hemangiomata, particularly with systemic symptoms, lymphadenopathy, or other benign vascular endothelial growths, for the potential development of MCD and other lymphoproliferative diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23426475     DOI: 10.1001/jamadermatol.2013.1552

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  11 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

Review 2.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.

Authors:  Gordan Srkalovic; Inga Marijanovic; Maya B Srkalovic; David C Fajgenbaum
Journal:  Bosn J Basic Med Sci       Date:  2017-05-20       Impact factor: 3.363

4.  Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Ruth-Anne Langan; Alberto Sada Japp; Helen L Partridge; Sheila K Pierson; Amrit Singh; Daniel J Arenas; Jason R Ruth; Christopher S Nabel; Katie Stone; Mariko Okumura; Anthony Schwarer; Fábio Freire Jose; Nelson Hamerschlak; Gerald B Wertheim; Michael B Jordan; Adam D Cohen; Vera Krymskaya; Arthur Rubenstein; Michael R Betts; Taku Kambayashi; Frits van Rhee; Thomas S Uldrick
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

5.  Transcriptome and unique cytokine microenvironment of Castleman disease.

Authors:  Anna Wing; Jason Xu; Wenzhao Meng; Aaron M Rosenfeld; Elizabeth Y Li; Gerald Wertheim; Michele Paessler; Adam Bagg; Dale Frank; Kai Tan; David T Teachey; Megan S Lim; Eline Luning Prak; David C Fajgenbaum; Vinodh Pillai
Journal:  Mod Pathol       Date:  2021-10-22       Impact factor: 8.209

Review 6.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

7.  Laparoscopic treatment for retroperitoneal hyaline-vascular type localized Castleman's disease (LCD) in the iliac vessel region.

Authors:  Aiwen Le; Lili Shan; Zhonghai Wang; Xiaoyun Dai; Tianhui Xiao; Rong Zhuo; Rui Yuan
Journal:  Int J Clin Exp Med       Date:  2015-11-15

8.  Intrapulmonary unicentric Castleman disease mimicking peripheral pulmonary malignancy.

Authors:  Yi Liu; Gang Chen; Xiaoming Qiu; Song Xu; Yi Wu; Renwang Liu; Qinghua Zhou; Jun Chen
Journal:  Thorac Cancer       Date:  2014-10-23       Impact factor: 3.500

9.  Bromangiomas-ipratropium bromide-associated angiomas.

Authors:  Curt Samlaska; Andrew Rackham
Journal:  JAAD Case Rep       Date:  2019-08-29

Review 10.  Idiopathic multicentric Castleman's disease: a systematic literature review.

Authors:  Amy Y Liu; Christopher S Nabel; Brian S Finkelman; Jason R Ruth; Razelle Kurzrock; Frits van Rhee; Vera P Krymskaya; Dermot Kelleher; Arthur H Rubenstein; David C Fajgenbaum
Journal:  Lancet Haematol       Date:  2016-03-17       Impact factor: 18.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.